$5.46
+0.03(0.55%)
Mkt Cap $755M
$1.57
$6.69
52-Week Range
At A Glance
1
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases.
2
Most recently: . Results of Operations and Financial Condition. On March 5, 2026, Compass Therapeutics, Inc. issued a press release announcing financial results for the year e (2026-03-05).
$755M
Market Cap
—
Revenue
-$50M
Net Income
Employees35
Fundamentals
How The Business Makes Money
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001738021
ISINUS20454B1044
CUSIP20454B104
Phone617 500 8099
Address80 Guest Street, Boston, MA, 02135, US
SEC EDGAR